Safety of the novel influenza viral vector *Brucella abortus* vaccine in pregnant heifers

Segurança de uma nova vacina vetorial empregando o vírus influenza para *Brucella abortus* em novilhas prenhes

Kaissar Tabynov\textsuperscript{1} Sholpan Ryskeldinova\textsuperscript{1} Zhailaubay Kydyrbayev\textsuperscript{1} Abylai Sansyzbay\textsuperscript{1}

**ABSTRACT**

The present study provides the first information about the safety of a new influenza viral vector vaccine expressing the *Brucella* ribosomal protein L7/L12 or Omp16 containing the adjuvant Montanide Gel01 in pregnant heifers. Immunization of pregnant heifers was conducted via the conjunctival (n=10) or subcutaneous (n=10) route using cross prime and booster vaccination schedules at an interval of 28 days. The vector vaccine was evaluated in comparison with positive control groups vaccinated with *B. abortus* S19 (n=10) or *B. abortus* RB51 (n=10) and a negative (PBS+Montanide Gel01; n=10) control group. Clinical studies, thermometry, assessment of local reactogenicity and observation of abortion showed that the vector vaccine via the conjunctival or subcutaneous route was completely safe for pregnant heifers compared to the commercial vaccines *B. abortus* S19 or *B. abortus* RB51. The only single adverse event was the formation of infiltration at the site of subcutaneous injection; this reaction was not observed for the conjunctival route.

**Key words:** *Brucella abortus*, vaccine, influenza viral vector, safety, pregnant heifer, thermometry, reactogenicity, abortion.

**INTRODUCTION**

Bovine brucellosis is caused by the Gram-negative bacterium *Brucella abortus* and can induce abortion and decrease fertility, and can also lead to chronic zoonotic infections in humans (GODFROID et al., 2005). At present, brucellosis among cattle is prevented using live attenuated vaccines *B. abortus* S19 or *B. abortus* RB51. These vaccines offer high protectiveness, but have a number of serious disadvantages, primarily related to their ability to induce abortion in pregnant cows (SCHURIG et al., 2002). Furthermore, both strains are pathogenic to humans (ASHFORD et al., 2004). The shortcomings of existing commercial vaccines create difficulties in eliminating infection in brucellosis hotspots, particularly in countries with low economic level; therefore there is a high demand for new, effective, and safe vaccines against *B. abortus* infection.

The objective of this research was to provide specific prophylaxis against *B. abortus*, and...
we proposed and generated a novel vector vaccine based on the recombinant influenza A virus subtypes H5N1 or H1N1 expressing the *Brucella* ribosomal protein L7/L12 or outer membrane protein-16 (Omp16). Our previous complex studies involving thermometry, clinical examination, hematology and blood biochemical analysis showed that the vector vaccine were completely safe for cattle compared to a commercial vaccine S19 (TABYNOV et al., 2014a). However, to completely confirm the safety of any kind of preventive preparation, especially brucellosis vaccines, is necessary to show that it does not induce abortion in vaccinated pregnant animals. On this basis, the purpose of the present study was to investigate the vaccine safety in pregnant heifers.

**MATERIAL AND METHODS**

**Bacterial strains**

The vaccine strains *B. abortus* S19 (Shchelkovsky Biokombinat, Moscow oblast, Russia) and *B. abortus* RB51 (Colorado Serum Company, Denver, CO, USA) were used in this study. Bacterial cells were cultured under aerobic conditions in *Brucella* Agar Base (Sigma-Aldrich, St. Louis, MO, USA) at 37°C. All experiments with live *Brucella* were performed in the Research Institute for Biological Safety Problems and the biosafety level was 3 for the facilities.

**Generation of influenza viral vectors**

All influenza viral vectors (IVV) were generated by a standard reverse genetics method using eight bidirectional plasmids pHW2000. The detailed procedure for generation of IVV has been described previously (TABYNOV et al., 2014b; TABYNOV et al., 2014c). A total of four IVV subtypes expressing the *Brucella* L7/L12 or Omp16 proteins from the ORF of the *NS1* gene were generated: H5N1 (Flu-NS1-124-L7/L12-H5N1, Flu-NS1-124-Omp16-H5N1) and H1N1 (Flu-NS1-124-L7/L12-H1N1 and Flu-NS1-124-Omp16-H1N1).

**Vaccine preparation**

Vaccines were prepared from the IVV Flu-NS1-124-L7/L12-H5N1, Flu-NS1-124-Omp16-H5N1, Flu-NS1-124-L7/L12-H1N1 and Flu-NS1-124-Omp16-H1N1; the vaccines were accumulated in 10-day-old embryonated chicken eggs (CE; Lohmann Tierzucht GmbH, Cuxhaven, Germany) at 34°C for 48h. The titer of the IVV was determined in CE, as previously described (TABYNOV et al., 2012). The allantoic suspensions of IVV with the same antigenic structure (H5N1 or H1N1) were combined in a single pool in a 1:1 ratio to obtain bivalent vaccine formulations, and then the mixtures of IVV (L7/L12+Omp16) were mixed in a 1:1 ratio with sterile stabilizing medium containing 12% peptone from casein (Sigma-Aldrich) and 6% saccharose (Sigma-Aldrich), mixed, aliquoted into 1mL ampoules, lyophilized and stored at 2-8 ºC. Immediately before administration (via the conjunctival or subcutaneous route), the lyophilized vaccine was resuspended (1 or 2mL per ampoule, depending on the route of administration) in a 20% solution of the adjuvant Montanide Gel01 (Seppic, Puteaux, France) in PBS.

**Animals**

A total of 50 pregnant (6-7 months pregnant; artificially inseminated) Kazakh white breed (meat direction) heifers aging 16-18 months-old were used in this study. All animals were seronegative for *B. abortus*, which was confirmed by analysis of blood serum using the Rose Bengal test (RBT; Antigen, Almaty, Kazakhstan), serum agglutination test (SAT; Microgen, Moscow, Russia), complement fixation test (CFT; Microgen) and enzyme-linked immunosorbent assays (ELISA; Brucella-Ab C-ELISA, Svanova Biotech AB, Sweden) according to the manufacturers’ instructions. Pregnancy was confirmed at an early stage (up to 60 days of pregnancy) using a hormonal method (progesterone concentration) and ultrasound and rectal palpation.

**Vaccination**

Pregnant heifers in the experimental groups were immunized twice via the conjunctival or subcutaneous route of administration at an interval of 28 days with vaccines generated from the IVV subtypes H5N1 (prime vaccination) and H1N1 (booster vaccination). The detailed animal immunization scheme is shown in table 1. Animals in the positive control groups (10 animals per group) were immunized once subcutaneously in the neck region (right side) with commercial vaccines S19 (8.0x10⁸CFU animal⁻¹) or RB51 (3.4x10⁸CFU animal⁻¹) according to the manufacturer’s instructions. Pregnant heifers in the negative control group were subcutaneously administered with 2.0mL of 20% Montanide Gel01 adjuvant in PBS. Each group of animals was kept in a separate room of a specialized facility for animal confinement and had free access to water and food throughout the experiment.

**Assessment of vaccine safety**

The safety of the vector vaccine via two different methods of administration (groups Flu-BA
Safety of the novel influenza viral vector *Brucella abortus* vaccine in pregnant heifers.

*Ciência Rural, v.46, n.1, jan, 2016.*

Immunization of pregnant heifers with the vector vaccine via either the conjunctival or subcutaneous routes did not have any negative impact on the overall clinical status (behavior, appetite, etc.) of the animals or their course of pregnancy throughout the observation period. The rectal temperature of the animals in the experimental groups (Flu-BA *c.* and Flu-BA *s.c.*) remained within normal limits (37.5-39.5°C) and had no statistically significant difference (*P*>0.05) from the negative control group (PBS+Montanide Gel01) during the observation period (Figure 1). No side effects (expiration, conjunctivitis, etc.) were observed at the site of conjunctival administration; however, at the subcutaneous injection site, formation of infiltrates was noted in 100% of animals; these infiltrates formed within 7 days after vaccination were up to 5cm in diameter and completely resorbed within 35 days after vaccination. It should be noted that a similar reactogenicity was observed in the animals of the negative control group.

In the positive control groups (S19 or RB51), no animals showed any signs of any disease or changes in behavior or appetite during the period of clinical observation, similarly to the animals in the negative control group. However, a significant (*P*<0.0001) increase in rectal temperature (up to 40.6°C) was observed in animal groups vaccinated with S19 (at 1 and 2 days post-IV) or RB51 (on day 1 post-IV; Figure 1) compared to the negative control group. Moreover, in 40% of animals vaccinated with S19, formation of infiltrates up to 7cm in diameter was noted at the injection site; the infiltrates completely resorbed within 14 days after vaccination. Additionally, in the animals vaccinated with S19, one calf aborted on day 56 after vaccination (approximately day 206 of pregnancy). Bacteriological and serological studies confirmed that abortion of this animal was caused by vaccination with S19 (smooth *Brucella* was isolated from the organs of the aborted fetus).

**DISCUSSION**

This paper is an important part of the authors’ research and aimed to develop a new effective and safe vaccine against *B. abortus*. Previous studies showed the IVV alone or in combination with the adjuvant Montanide Gel01 induced humoral and strong antigen-specific T-cell immune responses, and most importantly provided a high level of protectiveness comparable to that offered by a commercial S19 vaccine (TABYNOV et al., 2014c). We also showed that the vector vaccine in pregnant heifers provided good protection against *B. abortus* 544 infection comparable to commercial vaccines *B. abortus* S19 or *B. abortus* RB51 (TABYNOV et al., 2014d). All previous studies of the vaccine safety were conducted exclusively in heifers, and therefore there is no information available in pregnant heifers. Previously, we recommend the conjunctival method as the route of administration for cattle; however, this method is associated with certain difficulties,
primarily a low productivity as it takes 5-10 min to vaccinate one animal and there is a complexity on controlling the dosage due to back flow of the vaccine out of the conjunctival sac. Therefore, in addition to the conjunctival method, we also tested subcutaneous immunization, a more convenient and widely-used method, in this study.

This research, which included thermometry and assessment of local reactogenicity and abortion, showed that the vector vaccine was completely safe for pregnant heifers via the conjunctival or subcutaneous methods of administration. Only one negative reactogenic side-effect was associated with the vector vaccine, i.e. the formation of infiltration at the site of subcutaneous injection of the vaccine; such a reaction was not observed in animals vaccinated via the conjunctival route. This local adverse reaction is likely to be primarily due to the adjuvant, as a similar reaction was observed in the negative control group vaccinated with PBS+Montanide Gel01. In our opinion, the reactogenicity of this vaccine preparation could be reduced by decreasing the concentration of adjuvant to 10%, and also by reducing the volume used to resuspend the lyophilized vaccine (from 2mL to 1mL). In contrast, serious adverse events were observed in the positive control group vaccinated with S19, including both local (formation of infiltrates) and systemic reactions (increased body temperature), which were associated with abortion in one pregnant heifer. The adverse events observed in animals vaccinated with RB51 were minor and expressed exclusively as an increase in body temperature.

CONCLUSION

Thus, we can conclude that the new influenza viral vector vaccine against B. abortus administered via the conjunctival or subcutaneous route in a prime and booster immunization mode is completely safe (with the exception of a mild reaction for the subcutaneous route of administration) for pregnant heifers. Although safe via the conjunctival route, after taking measures to reduce the reactogenicity of the vector vaccines (volume reduction and adjuvant concentration), we assume the use of a subcutaneous route may enable practical application of these vector vaccines.

ACKNOWLEDGEMENTS

studying the safety of the vector vaccine. This work was carried out under the grant 1296/GF4 funded by the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan.

BIOETHICS AND BIOSECURITY COMMITTEE APPROVAL

This study was carried out in compliance with national and international laws and guidelines on animal handling. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Research Institute for Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan (Permit Number: 0713/115).

REFERENCES


